Psilocybin-Assisted Compassion Focused Therapy for Depression

Major depressive disorder remains highly prevalent and burdensome, and current psychotherapies and pharmacotherapies leave many patients without remission. Pots and colleagues note that psilocybin has emerged as a promising intervention for depression: it can alter glutamate signalling in key brain regions, produce changes in self-experience, and increase feelings of connectedness. Clinical trials using psilocybin with psychological support commonly adopt a preparatory–navigation–integration structure, but the psychotherapeutic content has often been non‑directive or minimally specified, and the contribution of an explicit psychotherapeutic model to clinical benefit is unclear. This paper sets out to embed psilocybin-assisted psychotherapy for depression within the theoretical and practical framework of Compassion Focused Therapy (CFT). The study aim is to present the rationale for selecting CFT, describe the compatibility of CFT with psilocybin-assisted therapy, and provide an operationalised treatment protocol and study design suggestions to examine its efficacy and feasibility. The authors propose that CFT practices may reinforce therapeutic processes during navigation (dosing) and integration, thereby enhancing clinical outcomes for depression.

Rather than reporting an empirical trial, Pots and colleagues describe the development of a manualised psilocybin‑assisted CFT protocol. The protocol was constructed from established psychedelic-assisted psychotherapy structures and CFT theory, and comprises 13 therapist‑led sessions. Each session contains therapist instructions, psychoeducation, an in‑session experiential exercise derived from CFT (for example soothing rhythm breathing), and homework (the protocol asks participants to practise roughly 2 hours per week); homework adherence is checked at the start of each session. The treatment is organised into three blocks. Preparatory sessions (sessions 1–3) teach the CFT conceptualisation of depression (including the ‘‘Tricky Brain’’ metaphor and the three‑circles model of threat, drive and soothing systems), introduce soothing rhythm breathing and compassion‑focused body practices, and begin work on building a compassionate self and on working with internal parts. At the end of the third preparatory session an intention for the first psilocybin navigation session is formulated; preparation for the second navigation session integrates learnings from the first. Navigation (psilocybin administration) sessions are conducted using a non‑directive stance and music playlists. Therapists allow self‑directed meaning‑making while using CFT formulations to support participants in bringing the compassionate self into difficult material and in relating to emerging parts. The CFT case conceptualisation is iteratively updated based on material from navigation sessions. Integration sessions combine debriefing of the psychedelic experience with explicit CFT exercises (compassionate attention, compassionate behaviour, compassionate imagery) and CFT homework tasks such as compassionate thought‑records, letter writing, and worksheets addressing the inner critic. The authors articulate a CFT therapeutic stance emphasising safety, non‑judgement, experiential learning, and tolerance of distress. For empirical evaluation, they propose a three‑arm randomised clinical trial comparing psilocybin‑assisted CFT, psilocybin with non‑directive psychological support, and a psilocybin‑only condition with minimal support (with safety measures in the latter). As an alternative for resource‑limited settings they suggest single case experimental designs, notably multiple baseline designs. Planned outcome measurement includes the GRID‑HAMD as primary outcome, and secondary measures such as the Mental Health Continuum‑Short Form (MHC‑SF), Compassion Engagement and Action Scales (CEAS), Types of Positive Affect Scale (TPAS, Safe Positive Affect subscale), Fears of Compassion Scales (FCS), and heart rate variability (HRV). Assessments are proposed at baseline, pre‑psilocybin sessions (week 4 and week 7) and at follow‑up (week 10). The authors also describe plans to develop a therapist manual and training based on contemporary CFT resources, but do not specify training duration or competency metrics.

This article does not report new trial data or empirical results; rather, it synthesises rationale and provides a treatment protocol. Pots and colleagues summarise prior findings that motivate their approach: earlier clinical studies have found moderate to large antidepressant effects of psilocybin in people with cancer‑related distress and in major depressive disorder, alongside generally promising tolerability. They also note literature suggesting that psilocybin can reduce negative affect and associated neural correlates, increase positive affect and social connectedness, and produce increases in self‑compassion and reductions in self‑criticism similar to those seen after compassion practices. Regarding CFT evidence, the authors cite meta‑analytic findings that compassion‑based interventions produce moderate to large effects on depression and well‑being across clinical and non‑clinical samples. No empirical evaluation of the presented psilocybin‑assisted CFT protocol is included in the extracted text, so there are no within‑paper effect sizes, response rates, or adverse‑event summaries to report.

Pots and colleagues argue that integrating CFT with psilocybin administration could strengthen therapeutic gains by providing participants with conceptual understanding and practical compassion skills to interpret and integrate psychedelic experiences. They propose that CFT and psilocybin may act synergistically because both stimulate affiliative or ‘‘soothing’’ systems, increase social connectedness, and reduce threat‑based responding; CFT offers structured practices to sustain and translate acute psychedelic insights into everyday changes in cognition, affect and behaviour. The authors position their protocol relative to alternative psychotherapeutic frameworks (for example CBT or ACT), emphasising that while these approaches change the relationship to thoughts and emotions, CFT specifically targets the cultivation of compassion and social safeness, which may be especially relevant for individuals high in shame and self‑criticism. They also note that some people with insecure attachment styles and high self‑criticism can find compassion practices challenging or distressing, and that affiliation‑focused interventions (including oxytocin or, plausibly, psychedelics) may have variable effects depending on attachment and self‑evaluative style; similar vulnerabilities might arise during psilocybin‑assisted CFT. Key limitations acknowledged by the authors include uncertainty about how much psychotherapeutic guidance is necessary to realise psilocybin's antidepressant effects and the absence of data on a potential dose–response relationship between psychotherapy intensity and outcomes. They caution that the protocol was developed specifically for psilocybin and depression and should not be generalised to other psychedelics or indications without further study. The authors further recognise that specific therapist competencies required to deliver psilocybin‑assisted CFT have not been empirically defined and that training programmes will be needed. Finally, they call for research comparing different therapeutic models and examining mechanisms of change and patient‑level moderators (for example attachment style or physiological characteristics) to determine which protocols best suit which patients.

The paper presents a manualised psilocybin‑assisted Compassion Focused Therapy protocol intended to fill a gap in guidance for psychotherapeutic content in psychedelic treatment for depression. Pots and colleagues conclude that the integrative CFT framework may enhance psilocybin therapy by fostering compassion, social connectedness and social safeness, and recommend empirical testing of the protocol. They propose feasible study designs (a three‑armed RCT or single case experimental designs) and advocate development of therapist training and a treatment manual as next steps.